Prevalence of Helicobacter pylori infection in long-term hemodialysis patients
|
|
- Berenice Waters
- 6 years ago
- Views:
Transcription
1 original article & 29 International Society of Nephrology Prevalence of Helicobacter pylori infection in long-term hemodialysis patients Mitsushige Sugimoto 1, Kyoko Sakai 2, Masakazu Kita 3, Jiro Imanishi 3 and Yoshio Yamaoka 1 1 Section of Gastroenterology, Department of Medicine, Michael E. DeBakey Veterans Affairs Medical Center, Baylor College of Medicine, Houston, Texas, USA; 2 Department of Gastroenterology and Hepatology, Nara City Hospital, Nara, Japan and 3 Department of Microbiology, Kyoto Prefectural University of Medicine, Kyoto, Japan Patients on hemodialysis often have gastrointestinal complications; however, it is unclear if Helicobacter pylori infection is present in these patients. Here we determined the prevalence of H. pylori infection in 539 Japanese hemodialysis patients by measuring serum anti-h. pylori IgG antibodies. Endoscopy was performed on 299 of these patients and the results were compared to 4 patients with normal renal function who had also undergone endoscopy and sero-testing. A second cohort of 478 dialysis patients, within the original group, was checked serologically for H. pylori infection three times over a four-year observation period. The prevalence of infection in these patients was significantly lower than in those patients with normal renal function, irrespective of the clinical outcomes. The prevalence of H. pylori infection significantly decreased as the duration of dialysis increased, particularly within the first four years following initiation of dialysis. About one-third of patients on dialysis for less than four years became serologically negative for H. pylori infection within this observation period. Our study suggests that although longterm dialysis patients have low prevalence of H. pylori, they still have significant gastroduodenal diseases, such as peptic ulcers, that require endoscopic follow-up. Kidney International (29) 75, 96 13; doi:1.138/ki.28.58; published online 8 October 28 KEYWORDS: Helicobacter pylori; hemodialysis; chronic renal failure; peptic ulcer Correspondence: Yoshio Yamaoka, Section of Gastroenterology, Department of Medicine, Michael E. DeBakey Veterans Affairs Medical Center (111D), Baylor College of Medicine, Rm 3A-32, 22 Holcombe Blvd, Houston, Texas 773, USA. yyamaoka@bcm.tmc.edu Received 15 April 28; revised 11 August 28; accepted 26 August 28; published online 8 October 28 Helicobacter pylori (H. pylori) is a spiral-shaped Gramnegative flagellate bacterium. Chronic H. pylori infection has close associations with gastrointestinal diseases, such as peptic ulcer (PU), gastric hyperplastic polyps, gastric adenoma, gastric cancer, and gastric mucosa-associated lymphoid tissue lymphoma. 1 3 Recently, increased evidence suggests that the development of some extragastrointestinal disorders including idiopathic thrombocytopenic purpura, chronic idiopathic urticaria, and iron deficiency anemia are also related with H. pylori infection of gastric mucosa. 4 6 In these infected patients, the eradication of H. pylori is recommended as the first-line therapy for the prevention and cure of gastroduodenal diseases. 1,7 Although there is no significant evidence that H. pylori infection is directly associated with progression of renal dysfunction, patients receiving chronic hemodialysis and continuous ambulatory peritoneal dialysis (CAPD) often incur gastrointestinal troubles over their long treatment period Patients with chronic renal failure (CRF) present with various clinical symptoms, including nausea, dyspepsia, appetite loss, epigastric discomfort, and heartburn, as well as histological, physiological, and functional disorders of the gastrointestinal system. 18,19 These symptoms not only decrease the quality of life of patients, but also may affect their nutrition status, thus contributing to the development of malnutrition, which is a potent predictor of morbidity and mortality in patients with CRF. Moreover, 25 75% of patients with CRF undergoing dialysis suffer from a number of gastrointestinal lesions and their complications (for example, gastric erosions, PUs, angiodysplasia, and gastrointestinal bleeding). 8 17,2 H. pylori infection is crucial in many gastrointestinal conditions not only in individuals with normal renal function, but also in CRF patients receiving chronic dialysis, CAPD, and kidney transplant. Recently, although associations between patients with CRF and the prevalence of H. pylori infection have been reported, 9 14,21 59 their results are still controversial, probably due to small number of studies and short duration periods. Only four previous studies examined more than 2 patients (maximum of 322 patients 2 ), and no previous studies examined patients with mean dialysis duration periods of 41 months. In addition, 96 Kidney International (29) 75, 96 13
2 M Sugimoto et al.: H. pylori infection and dialysis o r i g i n a l a r t i c l e only few reports evaluated the relationship between H. pylori infection and dialysis treatment duration. 41,49 Therefore, we aimed to clarify the prevalence of H. pylori infection in more than 5 patients receiving dialysis with a mean duration period of more than 8 years. Moreover, we first performed a follow-up survey to assess H. pylori infection in the same patient cohort receiving dialysis for 4 years. RESULTS Patients A total of 539 patients receiving dialysis at Tojinkai Hospital, Kyoto, Japan during April 1997 were enrolled in this study. A total of 4 patients with normal renal function who underwent endoscopy at the University Hospital of Kyoto Prefectural University of Medicine, Kyoto, Japan between January 1996 and April 1997 were also enrolled in this study. Among them 121 patients visited the hospital for annual health check irrespective of gastrointestinal symptoms and remaining patients for investigation of gastrointestinal symptoms. All patients were determined H. pylori status by serological test using anti-h. pylori immunoglobulin G (IgG) antibody at the beginning of this study in Accuracy of serological test for patient receiving dialysis treatment The detection of H. pylori status by anti-h. pylori IgG antibody in patients receiving dialysis treatment might be influenced by the impaired immune system, and might be judged as false-negative cases. To check the accuracy of this serological test, we performed 13 C-urea breath test as well as two invasive tests using biopsy specimens obtained during endoscopy (H. pylori culture and rapid urease test) for randomly selected 7 patients who had either positive or negative serological test. When at least one of alternative tests yielded positive results, we judged the patients as H. pylori positive and compared with the serological test. The specificity, sensitivity, positive predictive value, negative predictive value, and accuracy of serological test were 94.1, 97.2, 97., 94.6, and 95.7%, respectively, confirming that this serological test was reliable and accurate even for patients receiving dialysis treatment. Prevalence of H. pylori infection in patients receiving dialysis at the beginning of the study Demographic and clinical characteristics of patients enrolled at the beginning of the study (1997) are summarized in Table 1. The basement diseases in chronic dialysis patients were chronic glomerulonephritis (CGN) including IgA nephropathy, membranous nephropathy, minimal change, and antineutrophil cytoplasmic antibody-related nephritis (n ¼ 388), diabetes (n ¼ 13), and others including lupus nephritis, polycystic kidney, chronic pyelonephritis, and nephrosclerosis (n ¼ 48). There were no significant differences in age, sex, and symptom scores among different basement diseases of dialysis (Table 1). Gastrointestinal symptoms also had no association with H. pylori status and dialysis duration (data not shown). The prevalence of H. pylori infection and H. pylori IgG levels in patients with diabetic nephropathy was significantly higher than in the CGN group (P ¼.1 for each) (Table 1). In addition, the treatment period in patients with diabetic nephropathy was 4.9±.4 years, which was significantly shorter than those with the CGN group (9.2±.4 years, Po.1). The prevalence of H. pylori infection in patients receiving dialysis (mean duration of 8.4±.3 years) was 48.6% (95% confidence interval (CI): %, 262 of 539), which was significantly lower than in all patients with normal renal function (78.5%, 95% CI: %, 314 of 4, Po.1) as well as patients with normal renal function who visited the hospital for annual health check (69.4%, 95% CI: %, 84 of 121, P ¼.1) (Table 1). Importantly, the prevalence of H. pylori infection in patients receiving dialysis treatment for less than 1 year (74.1%, %, 4 of 54) was similar to annual health check patients with normal renal function (P ¼.1). The mean duration of dialysis treatment in H. pylori-positive patients (6.62±.4 years) was significantly shorter than in negative patients (9.45±.4 years, Po.1). Table 1 Patient demographics Patients with normal renal function Dialysis patients Annual health check Total CGN Diabetic nephritis Others Total P-value* P-value** n Sex (M/F) 59/62 223/ /169 55/48 23/25 296/ Age 56.6± ± ±.6 6.4± ± ± H. pylori+ (%) 84 (69.4) 314 (78.5) 179 (46.1) 62 (6.2) 21 (43.8) 262 (48.6).3 o.1 H. pylori IgG (U/ml) 22.3 ( ) 26.4 ( ) 8.7 ( ) 2.2 ( ) 8.9 ( ) 15.1 ( ).19 o.1 Dialysis period (year) NA NA 9.2±.4 4.9±.4 9.2± ±.3 o.1 Symptom scores (%) NT NT 1 (1 1) 1 (1 1) 1 (1 1) 1 (1 1) ±.7 (13.5) 1.4±.1 (15.2) 1.1±.1 (5.4) 1.4±.1 (13.) CGN, chronic glomerulonephritis, NA, not available, NT, not tested. Age and dialysis period are reported as mean±sd, and H. pylori IgG levels and symptom scores are presented as median (25 75% quartiles), mean±sd and percentage of patients with symptom. Patients with normal renal function did not test the symptom scoring, but only presence/absence of symptom. *Analyzed differences among three different basement diseases of hemodialysis. **Analyzed differences among dialysis patients and patients with normal renal function. Kidney International (29) 75,
3 o r i g i n a l a r t i c l e M Sugimoto et al.: H. pylori infection and dialysis Table 2 Endoscopic findings in dialysis patients and patients with normal renal function Patients with normal renal function Dialysis patients Diseases Annual health check Total CGN Diabetic nephritis Others Total n Gastritis 112 (92.6%)* 187 (46.8%)* 154 (75.5%) 49 (84.5%) 3 (81.1%) 233 (77.8%) Gastric ulcer 5 (4.1%) 116 (29.%) 24 (11.7%) 6 (1.3%) 4 (1.8%) 34 (11.4%) Duodenal ulcer 4 (3.3%) 72 (18.%) 15 (7.4%) 1 (1.7%) 3 (8.1%) 19 (6.4%) Gastric cancer (.%) 18 (4.5%) 3 (1.5%) 2 (3.4%) (.%) 5 (1.7%) Others (.%) 7 (2.5%) 8 (3.9%) (.%) (.%) 8 (2.7%) CGN, chronic glomerulonephritis. Others included patients with mucosa-associated lymphoid tissue lymphoma, submucosal tumor, and post-gastrectomy. *Po.5 (compared the prevalence with total of dialysis patients). Table 3 Relationship between endoscopic findings and H. pylori infection Patients with normal renal function Dialysis patients Diseases Annual health check CGN Diabetic nephritis Others Total P-value Gastritis 75/112 (67.%) 67/154 (43.5%) 28/49 (57.1%) 15/3 (5.%) 11/233 (47.2%) o.1 Gastric ulcer 5/5 (1%) 18/24 (75.%) 5/6 (83.3%) 2/4 (5.%) 25/34 (73.5%).189 Duodenal ulcer 4/4 (1%) 9/15 (6.%) /1 (%) 1/3 (33.3%) 1/19 (52.6%).77 Gastric cancer / (%) 1/3 (33.3%) 1/2 (5.%) / (%) 2/5 (4.%) Others / (%) 3/8 (37.5%) / (%) / (%) 3/8 (37.5%) Total 84/121 (69.4%) 98/24 (48.%) 34/58 (58.6%) 18/37 (48.6%) 15/299 (5.2%) o.1 CGN, chronic glomerulonephritis. Others included patients with mucosa-associated lymphoid tissue lymphoma, submucosal tumor, and post-gastrectomy. The data were demonstrated as number of H. pylori-positive patients per number of total patients with gastroduodenal disease (percentage of H. pylori-positive patients). P-value analyzed the comparison with annual health check patients with normal renal function and dialysis patients. Endoscopical finding in patients at the beginning of the study Endoscopic examination was performed in 299 patients receiving dialysis treatment as well as all patients with normal renal function. There were no significant differences in age, sex, dialysis period, and H. pylori status between dialysis patients with and without receiving endoscopy (data not shown). Endoscopic findings were divided into five diseases: simple gastritis or normal appearing mucosa without ulcer and malignancy (gastritis), gastric ulcer, duodenal ulcer, gastric cancer, and others (Table 2). Endoscopic examination of dialysis patients revealed gastritis in 233 patients (77.8%), gastric ulcer in 34 (11.4%), duodenal ulcer in 19 (6.4%), and gastric cancer in 5 (1.7%) patients (Table 2). In patients with normal renal function, only 46.8% (187 of 4) had gastritis (Po.1) probably due to the fact that patients with normal renal function were selected from patients who received endoscopy in the University Hospital where the frequency of patients visiting the hospital only for annual health check without symptoms was low. In fact, patients with normal renal function for annual health check revealed gastritis in 112 patients (92.6%), gastric ulcer in 5 (4.1%), and duodenal ulcer in 4 (3.3%) patients. As dialysis patients were not selected by the presence of gastrointestinal symptoms, we compared data of dialysis patients with those of only 121 patients with normal renal function for annual health check in subsequent analyses. Importantly, the prevalence of H. pylori infection was significantly lower in dialysis patients than in patients with normal renal function, irrespective of the clinical outcomes (Table 3). For example, among patients with gastritis alone, the prevalence of H. pylori infection was still significantly lower in dialysis patients than in patients with normal renal function (67. and 47.2%, Po.1). In addition, importantly, approximately half of the dialysis patients with duodenal ulcer (52.6%) were H. pylori negative although it is the consensus that most of the duodenal ulcer patients are infected with H. pylori (Table 3). In H. pylori-positive patients, 26.7% (4 of 15) of dialysis patients and only 1.7% (9 of 87) of patients with normal renal function developed severe gastroduodenal diseases (P ¼.1). In addition, 15.2% (22 of 145) of H. pylori-negative patients still developed severe gastroduodenal diseases, whereas none of H. pylori-negative patients with normal renal function ( of 9) developed severe gastroduodenal diseases. Overall, we could conclude that lower prevalence of H. pylori infection in dialysis patients than in patients with normal renal function was not due to different patterns of clinical outcomes. The frequency of PU (duodenal ulcer and gastric ulcer) in patients receiving dialysis treatment less than 1 years was similar between H. pylori infected and uninfected patients (23.7%, 28 of 118; 2.2%, 19 of 94). However, the frequency in patients receiving dialysis treatment equal or more than 1 years was significantly higher in H. pylori-infected patients (18.9%, 7 of 37) than in uninfected patients (4.%, 2 of 5) (P ¼.2). In addition, most ulcers in uninfected patients were healing to the red scar stage, and active ulcers were rare (data not shown). When dialysis patients were divided into two groups based on the presence or absence of gastroduodenal symptoms, there were no significant differences of the prevalence of each disease between two groups irrespective of H. pylori infection (Table 4). 98 Kidney International (29) 75, 96 13
4 M Sugimoto et al.: H. pylori infection and dialysis o r i g i n a l a r t i c l e Table 4 Gastroduodenal symptoms in relation to endoscopic findings and H. pylori infection in dialysis patients H. pylori positive, %(n=36) Patients with symptoms H. pylori negative, %(n=34) Total, %(n=7) H. pylori positive, %(n=226) Patients without symptoms H. pylori negative, %(n=243) Total, %(n=469) Gastritis Gastric ulcer Duodenal ulcer Gastric cancer 6 3 Others Others included patients with mucosa-associated lymphoid tissue lymphoma, submucosal tumor, and post-gastrectomy. Follow-up studies with anti-h. pylori IgG antibodies Of 539 dialysis patients, 46 patients in 1999 and 15 patients in 21 did not have the serological test due to death, withdrawn agreement, or change of hospital. In the remaining 478 dialysis patients, the basement diseases were CGN (n ¼ 346), diabetes (n ¼ 89), and others (n ¼ 43). We only analyzed 478 dialysis patients in subsequent analyses for comparison of three time points (1997, 1999, and 21). At the beginning of the study (1997), the prevalence of H. pylori infection gradually decreased until 4 years after starting dialysis, irrelevant of basement diseases, followed by a plateau (Figure 1a). At follow-up survey of the same patients at 2 (1999) and 4 years (21) after initiation, the prevalence of H. pylori infection in relation to dialysis duration showed similar patterns observed in 1997 (Figure 1b). This pattern showed that the prevalence of H. pylori infection decreased in the first 4 years of dialysis and plateauing after 5 years of treatment. The decreased patterns of the prevalence of H. pylori infection according to treatment period were similar irrespective of the basement diseases (data not shown). The prevalence of H. pylori infection in 1997, 1999, and 21 was 51.6% (95% CI: %, 247 of 478), 42.9% ( %, 25 of 478), and 38.3% ( %, 183 of 478), respectively, indicating that the infection rate gradually decreased during dialysis treatment (Figure 2a). In other words, 26.7% ( %, 66 of 247) of dialysis patients naturally cured H. pylori infection during the observation periods of 4 years, in particular diabetes patients (36.8%, %, 21 of 57) (Figure 2a; Table 5). When dialysis patients were divided into three groups according to treatment periods at the beginning of the study in 1997 ( 4 5 9, and equal or more than 1 years), the prevalence of H. pylori infection in patients receiving equal or more than 5 years of dialysis treatment showed that the patients did not naturally cure H. pylori infection (Figure 2b). A total of 36.2% ( %, 42 of 116) of patients receiving 4 years of dialysis treatment in 1997 naturally cured H. pylori infection during 4 years of observation (Figure 2b). In agreement with the prevalence of H. pylori infection, anti-h. pylori IgG antibody levels in 1997 (2. U/ml, 25 75% quartiles: ) were significantly decreased during 2 and 4 years of observation in 1999 (12.3, , Po.1) and in 21 (11.2, , Po.1; Figure 3a). Anti-H. pylori IgG antibody levels in patients receiving 4 years of dialysis treatment in 1997 (21., ) was also significantly H. pylori infection rate (%) H. pylori infection rate (%) Year decreased in 1999 (16.3, , Po.1) and in 21 (15.4, , Po.1; Figure 3b). In contrast, anti-h. pylori IgG antibody levels in patients receiving equal or more than 5 years of dialysis treatment in 1997 were unchanged during 2 and 4 years of observation (data not shown). DISCUSSION The prevalence of H. pylori infection in patients receiving CAPD, chronic dialysis, or kidney transplant was reported to be equal or lower compared to subjects with normal renal function in various populations. 9 13,21 59 Patients receiving dialysis had significantly lower prevalence of H. pylori Treatment period 8 1 Treatment period Year Figure 1 Prevalence of H. pylori infection. (a) Within the first 4 years of treatment, the infection rate was decreased irrelevant of basement membrane diseases causing chronic renal failure. The decreased patterns of the prevalence of H. pylori infection according to treatment period were similar irrespective of the basement diseases. Prevalence of H. pylori infection in different treatment periods: 1997, 1999, and 21 in 478 patients. (b) Infection rates of H. pylori in 1999 and 21 were similar to those observed in 1997 among patients and different treatment periods. *Po.5 (vs patients with treatment period of less than 1 year). Kidney International (29) 75,
5 o r i g i n a l a r t i c l e M Sugimoto et al.: H. pylori infection and dialysis H. pylori infection rate (%) H. pylori infection rate (%) P <.1 P < infection in five studies, 22,27,28,4,49 whereas only one study reported that dialysis patients had significantly higher infection rates. 14 In the present study, we investigated the largest number of dialysis patients with a variety of treatment periods, and found that the prevalence of H. pylori infection in dialysis patients with CRF was significantly lower than in patients with normal renal function. The infection rate gradually decreased with increased dialysis treatment periods. Treatment period CGN Diabetes Others 4 years 5 1 years 11 yrars Figure 2 Changes in H. pylori infection rate in 1997, 1999, and 21 among total patients, CGN patients, and patients with diabetes and others, and among different treatment period groups. (a) The H. pylori infection rate was gradually decreased irrespective of age, sex, and basement diseases according to chronic dialysis treatment. H. pylori infection in patients with diabetic nephropathy was significantly higher than that in the CGN group. *Po.5 (vs CGN and others groups). Changes in H. pylori infection rate in 1997, 1999, and 21 among different treatment period groups. (b) The H. pylori infection rate was significantly decreased according to chronic dialysis treatment in patients with a treatment period of less than 4 years. *Po.5 (vs infection rate in 1997). Table 5 The change of the prevalence of H. pylori infection in dialysis patients in a follow-up survey Year Total CGN Diabetic nephritis Others n % n % n % n % CGN, chronic glomerulonephritis; +, H. pylori infection positive;, H. pylori infection negative. By the 4-year follow-up period, we demonstrated that H. pylori infection decreased in dialysis patients among different treatment periods, and the decrease was observed only in patients receiving dialysis for equal or less than 4 years. Surprisingly, more than one-third (36.2%) of these patients receiving equal or less than 4 years of dialysis treatment had naturally cured H. pylori infection without eradication therapies with proton pump inhibitors and antibiotics. In Japan, renal transplantation is not well established compared to Europe and the United States. Therefore, patients receiving dialysis for a prolonged period (more than 1 years) are not rare. Only a few previous reports have evaluated the relationship between H. pylori infection and dialysis treatment period, 41,49 and those reports demonstrate that the mean dialysis duration in H. pylori-positive patients was significantly shorter than in uninfected patients, as confirmed in this study. Nakajima et al. 49 reported that the prevalence of H. pylori infection markedly decreased when the treatment duration was 2 years or more. However, in all these previous studies, only one time point was observed, making it impossible to confirm whether the same patients naturally cured the infection after the dialysis. Although 37 (83.7%) of 43 previous reports had no significant differences in the prevalence of H. pylori infection among CRF patients and individuals with normal renal function, most of those previous reports enrolled less than 1 dialysis patients with an observation period of less than 1 year. 9 14,21 59 A short dialysis treatment window might not reveal important findings, such as the observed decreased incidence of H. pylori within the first 4 years. We performed a meta-analysis of previous report data 9 14,21 59 and data in this study to offset type 2 errors in determining prevalence of H. pylori infection. The prevalence of H. pylori infection in patients with renal dysfunction receiving chronic dialysis and CAPD was 43.4% (95% CI: %, 1284 of 2962) and 34.8% ( %, 113 of 325), respectively. The prevalence in overall patients with renal dysfunction was 41.8% ( %), 1742 of 4171), which was significantly lower than in the individuals with normal renal function both with and without gastrointestinal symptoms (48.9%, %, 1284 of 2622, Po.1). Although the sample size of patients receiving CAPD and kidney transplant was small, we concluded that patients with renal dysfunction have a low prevalence of H. pylori infection. There are at least three explanations as to why dialysis patients have low prevalence of H. pylori infection: (1) blood urea levels as well as urea nitrogen levels in gastric secretions are higher in dialysis patients than in patients with normal renal function, and high urea levels inhibit H. pylori growth in the stomach; 6 (2) H. pylori might be eradicated upon antibiotic treatment, both because antibiotics are commonly used during the initial treatment periods, and because antibiotic concentrations are higher in patients with renal failure; (3) Patients receiving dialysis have higher levels of proinflammatory cytokines, including interleukin-1b, -6, -8, 1 Kidney International (29) 75, 96 13
6 M Sugimoto et al.: H. pylori infection and dialysis o r i g i n a l a r t i c l e ELISA (anti-h. pylori IgG) U/ml P <.1 P <.1 U/ml P <.1 P <.1 P <.1 P <.1 1 ELISA (anti-h. pylori IgG) Figure 3 Four years follow-up of anti-h. pylori IgG antibody. All patients receiving dialysis (a) and patients with dialysis period of less than 4 years (b). In all patients receiving dialysis and patients with a treatment period of less than 4 years, the median anti-h. pylori IgG antibody level in 1997 was significantly higher than in 1999 and 21. and tumor necrosis factor, from activated inflammatory cells infiltrating the gastric mucosa. 61 As a result, gastric atrophy progresses, accompanied by increased ph, and finally H. pylori are not able to live in gastric mucosa. 62 In this study, there was no significant difference in the prevalence of H. pylori infection between patients with normal renal function and patients receiving less than 1 year of dialysis treatment. Therefore, urea concentration and antibiotic usage are unlikely contributors to decrease the prevalence of infection. One possible explanation for decreased H. pylori prevalence is severe inflammation resulting from dialysis, and progression to gastric atrophy. However, further studies to investigate the histopathology of gastric inflammation and atrophy are needed. Dialysis patients may have a higher risk of gastric mucosal damages compared with individuals with normal renal function by systemic and/or local chronic circulatory failure, 63,64 hypergastrinemia, 42 high ammonia levels, 26 and enhanced inflammation. Moreover, most dialysis patients also receive anticoagulant drugs for hypertension and brain infarction and/or heparin treatment. Therefore, patients often incurred massive hemorrhage from either PUs or gastric erosions. Importantly, we found that approximately half of the dialysis patients with duodenal ulcer were H. pylori negative although it is the consensus that most of the duodenal ulcer patients are infected with H. pylori. In addition, 15.2% (22 of 145) of H. pylori-negative patients still developed severe gastroduodenal diseases, whereas none of H. pylori-negative patients with normal renal function ( of 9) developed severe gastroduodenal diseases. Sotoudehmanesh et al. 1 also reported that H. pylori-negative dialysis patients frequently revealed any erosions in stomach and/or duodenum. These data indicate that not only H. pyloripositive dialysis patients, but also H. pylori-negative dialysis patients should receive endoscopic examination to prevent potentially destructive gastrointestinal events. In general, gastroduodenal symptoms are one of major triggers to find out PU and neoplastic diseases in healthy individuals. However, long-term dialysis patients often report decreased sensory disturbance, and in the present study the gastrointestinal symptoms of dialysis patients had no association with endoscopically monitored gastrointestinal diseases, which is in agreement with a previous report. 57 Gastrointestinal symptoms in dialysis patients might be caused not only by H. pylori infection, but also by high urea levels, decline of gastrointestinal motility, and amyloid protein deposition. In the present study, there were no significant differences of the prevalence of each disease between dialysis patients with and without gastroduodenal symptoms irrespective of H. pylori infection (Table 4). Dialysis patients may frequently develop PUs and erosion without gastrointestinal symptoms, and therefore, patients receiving dialysis irrespective to gastroduodenal symptoms should undergo endoscopic evaluation. One important question is whether H. pylori eradication therapies are necessary for H. pylori-infected dialysis patients. Thedatathatmorethanone-thirdofthepatientsreceiving equalorlessthan4yearsofdialysistreatmenthadnaturally cured H. pylori infection, and that approximately half of the dialysis patients with duodenal ulcer were H. pylori negative indicate that the eradication therapy might be meaningless. However, we showed that the frequency of PU in patients receiving dialysis treatment equal or more than 1 years was significantly higher in H. pylori-infected patients than in uninfected patients and most ulcers in uninfected patients were healing to the red scar stage, and active ulcers were rare. We therefore recommend receiving eradication therapies for H. pylori-infected dialysis patients, especially for patients receiving dialysis treatment for long time (for example, 5 years or more) where the chance of natural eradication becomes rare. We also demonstrated that the prevalence of H pylori infection in diabetic nephropathy patients was significantly higher than in the CGN group. Although the data on the prevalence of H. pylori infection in patients with type 2 diabetes remain contradictory, 65,66 a higher infection rate may be present due to an impaired immune system. 67 However, in the present study, patients with diabetes showed a decreased infection rate after the start of dialysis; therefore immunosuppression observed in diabetic patients should be considered independent of H. pylori infection. In conclusion, we considered that although the prevalence of H. pylori in Japanese patients receiving dialysis decreased Kidney International (29) 75,
7 o r i g i n a l a r t i c l e M Sugimoto et al.: H. pylori infection and dialysis in about 6% of patients within the first 4 years of dialysis, long-term dialysis patients irrespective of gastric symptoms and H. pylori infection should receive endoscopic check-ups and essential medication of acid-inhibitory drugs (for example, proton pomp inhibitors) to reduce the chance of developing severe gastroduodenal diseases. Moreover, we recommend receiving eradication therapies for H. pyloriinfected dialysis patients, especially for patients receiving dialysis for 5 years or more where the chance of natural eradication becomes rare. The clinical protocol for a detailed endoscopic check-up and eradication therapy for dialysis patients should be evaluated in future studies. MATERIALS AND METHODS Patients A total of 539 patients receiving chronic dialysis and 4 patients with normal renal function were enrolled in this study. The criteria for control patients were plasma creatinine levels less than 1.2 mg/1 ml and BUN levels less than 25 mg/1 ml. We administered a questionnaire regarding the severity of common gastrointestinal symptoms including dyspepsia, vomiting, nausea, epigastralgia, and heartburn. The dialysis patients were asked to rank the severity of the symptoms from 1 to 5 based on the frequencies of the symptoms (1, asymptomatic; 2, mild symptoms: 1 3 days a month; 3, moderate symptoms: 1 3 days a week; 4, severe symptoms: 4 6 days a week; and 5, very severe symptoms: everyday). No patients enrolled in the study received previous treatment for H. pylori infection. The research design was approved by the ethics committee and informed consent was obtained from all patients. H. pylori infection criteria and follow-up of anti-h. pylori IgG antibody by ELISA In all 539 dialysis patients and 4 patients with normal renal function enrolled in this study, H. pylori status was determined using a serum enzyme-linked immunosorbent assay (ELISA) test (Eiken Chemical, Tokyo, Japan) at the beginning of the study (1997). In addition, in 478 patients receiving chronic dialysis, follow-up ELISA test was also performed 2 and 4 years after (1999 and 21). A positive reaction was considered 42 U/ml. When were 15 2 U/ml (borderline), the ELISA test was repeated within 1 month. If the titer was still within 15 2 U/ml, H. pylori infection was evaluated by 13 C-urea breath test, culture, and/or rapid urease test. When at least one of alternative tests was positive, we judged the patients as H. pylori infection positive. Endoscopic check-up Information about gastroduodenal diseases was obtained from 299 patients receiving hemodialysis and all 4 patients with normal renal function. Endoscopy was performed for patients receiving chronic dialysis between May 1996 and April 1998 and for patients with normal renal function between January 1996 and April H. pylori-related diseases were diagnosed by endoscopy and histopathology. Endoscopic findings were divided into five diseases: simple gastritis or normal appearing mucosa without ulcer and malignancy (gastritis), gastric ulcer, duodenal ulcer, gastric cancer, and others. PUs with red scars were categorized as ulcers, but those with white scars (completely cured) were considered simple gastritis. Data analysis Statistical differences in demographic characteristics (mean age, men/women), prevalence of H. pylori, frequency of gastrointestinal diseases, and treatment period among different disease groups were determined by one-way analysis of variance or the w 2 -test. To determine whether anti-h. pylori IgG levels differed between the three time points, Wilcoxon s signed-rank test was used when significant differences were observed by Friedmann s test. Statistically significant differences in symptom scores were determined using the Mann Whitney U-test when significant differences were observed by the Kruskal Wallis test. Parametric data are presented as mean±s.d., and nonparametric data as median (25 75% quartiles). All P-values were two sided, and P-values o.5 were considered statistically significant. DISCLOSURE All the authors declared no competing interests. ACKNOWLEDGMENTS The project described was supported by grant number R1 DK62813 from National Institutes of Health (NIH). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. We thank Dr Yoshiko Masugi, Dr Koji Okino, and all staffs in Tojinkai hospital, Kyoto, Japan for obtaining informed consent and for providing samples. We also thank Dr Takeshi Okanoue and Dr Shoji Mitsufuji (Kyoto Prefectural University of Medicine, Kyoto, Japan) for providing samples. We especially thank Dr Tadashi Kodama (Second Okamoto Hospital, Kyoto, Japan) for providing prudent advice. REFERENCES 1. Uemura N, Okamoto S, Yamamoto S et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 21; 345: Hopkins RJ, Girardi LS, Turney EA. Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: a review. Gastroenterology 1996; 11: Wotherspoon AC, Doglioni C, de Boni M et al. Antibiotic treatment for low-grade gastric MALT lymphoma. Lancet 1994; 343: Gasbarrini A, Franceschi F, Tartaglione R et al. Regression of autoimmune thrombocytopenia after eradication of Helicobacter pylori. Lancet 1998; 352: Tebbe B, Geilen CC, Schulzke JD et al. Helicobacter pylori infection and chronic urticaria. J Am Acad Dermatol 1996; 34: Annibale B, Marignani M, Monarca B et al. Reversal of iron deficiency anemia after Helicobacter pylori eradication in patients with asymptomatic gastritis. Ann Intern Med 1999; 131: Take S, Mizuno M, Ishiki K et al. The effect of eradicating helicobacter pylori on the development of gastric cancer in patients with peptic ulcer disease. Am J Gastroenterol 25; 1: Ala-Kaila K. Upper gastrointestinal findings in chronic renal failure. Scand J Gastroenterol 1987; 22: Sezer S, Ibis A, Ozdemir BH et al. Association of Helicobacter pylori infection with nutritional status in hemodialysis patients. Transplant Proc 24; 36: Sotoudehmanesh R, Ali Asgari A, Ansari R et al. Endoscopic findings in end-stage renal disease. Endoscopy 23; 35: Prakash J, Agrawal BK. Upper gastrointestinal mucosal lesions in chronic renal failure. Indian J Gastroenterol 1991; 1: Gheissari A, Rajyaguru V, Kumashiro R et al. Gastrointestinal hemorrhage in end stage renal disease patients. Int Surg 199; 75: Tsai CJ, Hwang JC. Investigation of upper gastrointestinal hemorrhage in chronic renal failure. J Clin Gastroenterol 1996; 22: Khedmat H, Ahmadzad-Asl M, Amini M et al. Gastro-duodenal lesions and Helicobacter pylori infection in uremic patients and renal transplant recipients. Transplant Proc 27; 39: Milito G, Taccone-Gallucci M, Brancaleone C et al. Assessment of the upper gastrointestinal tract in hemodialysis patients awaiting renal transplantation. Am J Gastroenterol 1983; 78: Milito G, Taccone-Gallucci M, Brancaleone C et al. The gastrointestinal tract in uremic patients on long-term hemodialysis. Kidney Int 1985; 17: S157 S Musola R, Franzin G, Mora R et al. Prevalence of gastroduodenal lesions in uremic patients undergoing dialysis and after renal transplantation. Gastrointest Endosc 1984; 3: Kidney International (29) 75, 96 13
8 M Sugimoto et al.: H. pylori infection and dialysis o r i g i n a l a r t i c l e 18. Var C, Gultekin F, Candan F et al. The effects of hemodialysis on duodenal and gastric mucosal changes in uremic patients. Clin Nephrol 1996; 45: Kang JY, Ho KY, Yeoh KG et al. Peptic ulcer and gastritis in uraemia, with particular reference to the effect of Helicobacter pylori infection. J Gastroenterol Hepatol 1999; 14: Wee A, Kang JY, Ho MS et al. Gastroduodenal mucosa in uraemia: endoscopic and histological correlation and prevalence of helicobacterlike organisms. Gut 199; 31: Offerhaus GJ, Kreuning J, Valentijn RM et al. Campylobacter pylori: prevalence and significance in patients with chronic renal failure. Clin Nephrol 1989; 32: Shousha S, Arnaout AH, Abbas SH et al. Antral Helicobacter pylori in patients with chronic renal failure. J Clin Pathol 199; 43: Ala-Kaila K, Vaajalahti P, Karvonen AL et al. Gastric Helicobacter and upper gastrointestinal symptoms in chronic renal failure. Ann Med 1991; 23: Davenport A, Shallcross TM, Crabtree JE et al. Prevalence of Helicobacter pylori in patients with end-stage renal failure and renal transplant recipients. Nephron 1991; 59: Loffeld RJ, Peltenburg HG, vd Oever H et al. Prevalence of Helicobacter pylori antibodies in patients on chronic intermittent haemodialysis. Nephron 1991; 59: Neithercut WD, Rowe PA, el Nujumi AM et al. Effect of Helicobacter pylori infection on intragastric urea and ammonium concentrations in patients with chronic renal failure. J Clin Pathol 1993; 46: Jaspersen D, Fassbinder W, Heinkele P et al. Significantly lower prevalence of Helicobacter pylori in uremic patients than in patients with normal renal function. J Gastroenterol 1995; 3: De Vecchi AF, Quatrini M, Boni F et al. Epidemiology of Helicobacter pylori in dialysis patients. Perit Dial Int 1995; 15: Luzza F, Imeneo M, Maletta M et al. Helicobacter pylori-specific IgG in chronic haemodialysis patients: relationship of hypergastrinaemia to positive serology. Nephrol Dial Transplant 1996; 11: Seyrek N, Kocabas E, Hazar S et al. Helicobacter pylori antibodies in patients on chronic hemodialysis. Nephron 1996; 72: Krawczyk W, Gorna E, Suwala J et al. Frequency of Helicobacter pylori infection in uremic hemodialyzed patients with antral gastritis. Nephron 1996; 74: Abu Farsakh NA, Roweily E, Rababaa M et al. Brief report: evaluation of the upper gastrointestinal tract in uraemic patients undergoing haemodialysis. Nephrol Dial Transplant 1996; 11: Hruby Z, Myszka-Bijak K, Gosciniak G et al. Helicobacter pylori in kidney allograft recipients: high prevalence of colonization and low incidence of active inflammatory lesions. Nephron 1997; 75: Antoniou S, Dimitriadis A, Kliridou M et al. Prevalence of Helicobacter pylori antibodies in CAPD patients. Nephron 1997; 75: Moustafa FE, Khalil A, Abdel Wahab M et al. Helicobacter pylori and uremic gastritis: a histopathologic study and a correlation with endoscopic and bacteriologic findings. Am J Nephrol 1997; 17: Ozgur O, Boyacioglu S, Ozdogan M et al. Helicobacter pylori infection in haemodialysis patients and renal transplant recipients. Nephrol Dial Transplant 1997; 12: Munoz de Bustillo E, Sanchez Tomero JA, Sanz JC et al. Eradication and follow-up of Helicobacter pylori infection in hemodialysis patients. Nephron 1998; 79: Fabrizi F, Martin P, Dixit V et al. Epidemiology of Helicobacter pylori in chronic haemodialysis patients using the new RIBA H. pylori SIA. Nephrol Dial Transplant 1999; 14: Araki H, Miyazaki R, Matsuda T et al. Significance of serum pepsinogens and their relationship to Helicobacter pylori infection and histological gastritis in dialysis patients. Nephrol Dial Transplant 1999; 14: Misra V, Misra SP, Dwivedi M et al. Decreased sensitivity of the ultrarapid urease test for diagnosing Helicobacter pylori in patients with chronic renal failure. Pathology 1999; 31: Yildiz A, Besisik F, Akkaya V et al. Helicobacter pylori antibodies in hemodialysis patients and renal transplant recipients. Clin Transplant 1999; 13: Gur G, Boyacioglu S, Gul C et al. Impact of Helicobacter pylori infection on serum gastrin in haemodialysis patients. Nephrol Dial Transplant 1999; 14: Huang JJ, Huang CJ, Ruaan MK et al. Diagnostic efficacy of (13)C-urea breath test for Helicobacter pylori infection in hemodialysis patients. Am J Kidney Dis 2; 36: Emir S, Bereket G, Boyacioglu S et al. Gastroduodenal lesions and Helicobacter pylori in children with end-stage renal disease. Pediatr Nephrol 2; 14: Aguilera A, Codoceo R, Bajo MA et al. Helicobacter pylori infection: a new cause of anorexia in peritoneal dialysis patients. Perit Dial Int 21; 21(Suppl 3): S152 S Schoonjans R, Van VB, Vandamme W et al. Dyspepsia and gastroparesis in chronic renal failure: the role of Helicobacter pylori. Clin Nephrol 22; 57: Fabbian F, Catalano C, Bordin V et al. Esophagogastroduodenoscopy in chronic hemodialysis patients: 2-year clinical experience in a renal unit. Clin Nephrol 22; 58: Tsukada K, Miyazaki T, Katoh H et al. Seven-day triple therapy with omeprazole, amoxycillin and clarithromycin for Helicobacter pylori infection in haemodialysis patients. Scand J Gastroenterol 22; 37: Nakajima F, Sakaguchi M, Amemoto K et al. Helicobacter pylori in patients receiving long-term dialysis. Am J Nephrol 22; 22: Marsenic O, Peco-Antic A, Perisic V et al. Upper gastrointestinal lesions in children on chronic haemodialysis. Nephrol Dial Transplant 23; 18: Strid H, Simren M, Stotzer PO et al. Delay in gastric emptying in patients with chronic renal failure. Scand J Gastroenterol 24; 39: Lopez T, Quesada M, Almirall J et al. Usefulness of non-invasive tests for diagnosing Helicobacter pylori infection in patients undergoing dialysis for chronic renal failure. Helicobacter 24; 9: Nakajima F, Sakaguchi M, Oka H et al. Prevalence of Helicobacter pylori antibodies in long-term dialysis patients. Nephrology (Carlton) 24; 9: Al-Mueilo SH. Gastroduodenal lesions and Helicobacter pylori infection in hemodialysis patients. Saudi Med J 24; 25: Trimarchi H, Forrester M, Schropp J et al. Low initial vitamin B12 levels in Helicobacter pylori positive patients on chronic hemodialysis. Nephron Clin Pract 24; 96: c28 c Blusiewicz K, Rydzewska G, Rydzewski A. Gastric juice ammonia and urea concentrations and their relation to gastric mucosa injury in patients maintained on chronic hemodialysis. Rocz Akad Med Bialymst 25; 5: Lui SL, Wong WM, Ng SY et al. Seroprevalence of Helicobacter pylori in Chinese patients on continuous ambulatory peritoneal dialysis. Nephrology (Carlton) 25; 1: Lentine KL, Parsonnet J, Taylor I et al. Associations of serologic markers of infection and inflammation with vascular disease events and mortality in American dialysis patients. Clin Exp Nephrol 26; 1: Altay M, Turgut F, Akay H et al. Dyspepsia in Turkish patients on continuous ambulatory peritoneal dialysis. Int Urol Nephrol 28; 4: Gladziwa U, Haase G, Handt S et al. Prevalence of Helicobacter pylori in patients with chronic renal failure. Nephrol Dial Transplant 1993; 8: Hwang IR, Kodama T, Kikuchi S et al. Effect of interleukin 1 polymorphisms on gastric mucosal interleukin 1beta production in Helicobacter pylori infection. Gastroenterology 22; 123: Wesdorp RI, Falcao HA, Banks PB et al. Gastrin and gastric acid secretion in renal failure. Am J Surg 1981; 141: Block GA, Raggi P, Bellasi A et al. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 27; 71: Nakamura S, Sasaki O, Nakahama H et al. Clinical characteristics and survival in end-stage renal disease patients with arteriosclerosis obliterans. Am J Nephrol 22; 22: Anastasios R, Goritsas C, Papamihail C et al. Helicobacter pylori infection in diabetic patients: prevalence and endoscopic findings. Eur J Intern Med 22; 13: Bener A, Micallef R, Afifi M et al. Association between type 2 diabetes mellitus and Helicobacter pylori infection. Turk J Gastroenterol 27; 18: Bytzer P, Talley NJ, Leemon M et al. Prevalence of gastrointestinal symptoms associated with diabetes mellitus: a population-based survey of 15, adults. Arch Intern Med 21; 161: Kidney International (29) 75,
Original Article. Downloaded from iau-tmuj.ir at 0: on Saturday February 16th 2019
> >>?> @>> @ 3 6 > Original Article @>??> @? @> > @??> 4 3?> < @ < @> @> < < @? @ @>> @ @>> < >> @ @? @@ < @ > @>> @ @>> < @ @? @@ < @? > @>> @ @>> < >> @ @? @@ < @??> @ >
More informationPrevalence of Helicobacter pylori in Patients with End Stage Renal Disease
2000;20:97-102 Helicobacter pylori Prevalence of Helicobacter pylori in Patients with End Stage Renal Disease Do Ha Kim, M.D., Hwoon-Yong Jung, M.D., Suk-Kyun Yang, M.D. Weon-Seon Hong, M.D. and Young
More informationUpper Gastrointestinal Manifestations in Chronic Renal Failure Through Upper Gastrointestinal Endoscopy
Original Article Print ISSN: 2321-6379 Online ISSN: 2321-595X DOI: 10.17354/ijss/2017/249 Upper Gastrointestinal Manifestations in Chronic Renal Failure Through Upper Gastrointestinal Endoscopy Madavaram
More informationHelicobacter and gastritis
1 Helicobacter and gastritis Dr. Hala Al Daghistani Helicobacter pylori is a spiral-shaped gram-negative rod. H. pylori is associated with antral gastritis, duodenal (peptic) ulcer disease, gastric ulcers,
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: helicobacter_pylori_testing 01/01/2019 N/A 01/01/2020 01/01/2019 Policy Effective April 1, 2019 Description
More informationPrevalence of Asymptomatic Gastroduodenal Lesions and Helicobacter pylori Infection in Kidney Transplant Candidates
Prevalence of Asymptomatic Gastroduodenal Lesions and Helicobacter pylori Infection in Kidney Transplant Candidates J Med Assoc Thai 2014; 97 (Suppl. 11): S62-S68 Full text. e-journal: http://www.jmatonline.com
More informationHelicobacter Pylori Testing HELICOBACTER PYLORI TESTING HS-131. Policy Number: HS-131. Original Effective Date: 9/17/2009
Easy Choice Health Plan, Inc. Harmony Health Plan of Illinois, Inc. Missouri Care, Inc. Ohana Health Plan, a plan offered by WellCare Health Insurance of Arizona, Inc. WellCare Health Insurance of Illinois,
More informationAssessment of symptomatic response as predictor of Helicobacter pylori status following eradication therapy in patients with ulcer
618 University Department of Medicine and Therapeutics, Western Infirmary, Glasgow G11 6NT, UK K E L McColl A El-Nujumi L S Murray E M El-Omar A Dickson A W Kelman T E Hilditch Correspondence to: Professor
More informationUpper Gastrointestinal Disorders in Children with End -Stage Renal Disease
ORIGINAL REPORT Upper Gastrointestinal Disorders in Children with End -Stage Renal Disease Seyed Taher Esfahani *, Abbas Madani, Neamatollah Ataei, Mahdi Nadjafi 2, Parvin Mohseni, Bahar Allahverdi 2,
More informationEarly release, published at on November 14, Subject to revision.
CMAJ Early release, published at www.cmaj.ca on November 14, 2011. Subject to revision. Research Incidence of bleeding from gastroduodenal ulcers in patients with end-stage renal disease receiving hemodialysis
More informationComparative study of invasive methods for diagnosis of Helicobacter pylori in humans
ISSN: 2319-7706 Volume 2 Number 7 (2013) pp. 63-68 http://www.ijcmas.com Original Research Article Comparative study of invasive methods for diagnosis of Helicobacter pylori in humans V.Subbukesavaraja
More informationJournal of Medical Science & Technology
Journal of Medical Science & Technology Original Article Helicobacter Pylori Colonization in Patients with Chronic Renal Failure K. Sunil Naik 1, S.vijaya 2 Baswaraj Munge 3 Open Access 1 Assistant professor,
More informationUrea Breath Test for Diagnosis of Helicobactor pylori. Original Policy Date 12:2013
MP 2.04.04 Urea Breath Test for Diagnosis of Helicobactor pylori Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date 12:2013 Return to Medical Policy Index
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/48400
More informationClinical Policy: Helicobacter Pylori Serology Testing Reference Number: CP.MP.153
Clinical Policy: Reference Number: CP.MP.153 Effective Date: 12/17 Last Review Date: 12/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory and
More informationThe Nobel Prize in Physiology or Medicine for 2005
The Nobel Prize in Physiology or Medicine for 2005 jointly to Barry J. Marshall and J. Robin Warren for their discovery of "the bacterium Helicobacter pylori and its role in gastritis and peptic ulcer
More informationHelicobacter pylori:an Emerging Pathogen
Bacteriology at UW-Madison Bacteriology 330 Home Page Helicobacter pylori:an Emerging Pathogen by Karrie Holston, Department of Bacteriology University of Wisconsin-Madison Description of Helicobacter
More informationPEPTIC ULCER DISEASE JOHN R SALTZMAN, MD. Director of Endoscopy Brigham and Women s Hospital Professor of Medicine Harvard Medical School
PEPTIC ULCER DISEASE JOHN R SALTZMAN, MD Director of Endoscopy Brigham and Women s Hospital Professor of Medicine Harvard Medical School No disclosures Disclosures Overview Causes of peptic ulcer disease
More informationWhat is the status of Sequential Therapy Versus Standard Triple- Drug Therapy in peptic ulcer disease in eradicating H pylori?
What is the status of Sequential Therapy Versus Standard Triple- Drug Therapy in peptic ulcer disease in eradicating H pylori? Sequential Therapy Versus Standard Triple- Drug Therapy for Helicobacter pylori
More informationCOMPARISON OF ONCE-A-DAY VERSUS TWICE-A-DAY CLARITHROMYCIN IN TRIPLE THERAPY FOR HELICOBACTER PYLORI ERADICATION
Phil J Gastroenterol 2006; 2: 25-29 COMPARISON OF ONCE-A-DAY VERSUS TWICE-A-DAY CLARITHROMYCIN IN TRIPLE THERAPY FOR HELICOBACTER PYLORI ERADICATION Marianne P Collado, Ma Fatima P Calida, Peter P Sy,
More informationEndoscopic atrophic classification before and after H. pylori eradication is closely associated with histological atrophy and intestinal metaplasia
E311 before and after H. pylori eradication is closely associated with histological atrophy and intestinal metaplasia Authors Institution Masaaki Kodama, Tadayoshi Okimoto, Ryo Ogawa, Kazuhiro Mizukami,
More informationEffect of Helicobacter pylori infection and its eradication on nutrition
Aliment Pharmacol Ther 2002; 16: 799 806. Effect of Helicobacter pylori infection and its eradication on nutrition T. FURUTA*, N. SHIRAI*, F. XIAO*, M. TAKASHIMA* & H. HANAI *First Department of Medicine
More informationTreatment of Helicobacter pylori Infection
Treatment of Helicobacter pylori Infection Epidemiology of H. pylori infection (North America) Which are the high risk groups? Epidemiology of H. pylori infection (North America) Which are the high risk
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 4,000 116,000 120M Open access books available International authors and editors Downloads Our
More informationProton Pump Inhibitors Drug Class Prior Authorization Protocol
Proton Pump Inhibitors Drug Class Prior Authorization Protocol Line of Business: Medi-Cal P&T Approval Date: November 15, 2017 Effective Date: January 1, 2018 This policy has been developed through review
More informationNational Digestive Diseases Information Clearinghouse
Gastritis National Digestive Diseases Information Clearinghouse U.S. Department of Health and Human Services NATIONAL INSTITUTES OF HEALTH What is gastritis? Gastritis is a condition in which the stomach
More informationCase Report Features of the Atrophic Corpus Mucosa in Three Cases of Autoimmune Gastritis Revealed by Magnifying Endoscopy
Volume 2012, Article ID 368160, 4 pages doi:10.1155/2012/368160 Case Report Features of the Atrophic Corpus Mucosa in Three Cases of Autoimmune Gastritis Revealed by Magnifying Endoscopy Kazuyoshi Yagi,
More informationAssociation of Helicobacter pylori infection with Atrophic gastritis in patients with Dyspepsia
ADVANCES IN BIORESEARCH Adv. Biores., Vol 8 [3] May 2017: 137-141 2017 Society of Education, India Print ISSN 0976-4585; Online ISSN 2277-1573 Journal s URL:http://www.soeagra.com/abr.html CODEN: ABRDC3
More informationHigh Recurrence Rate of Idiopathic Peptic Ulcers in Long-Term Follow-up
Gut and Liver, Vol. 7, No. 2, March 2013, pp. 175-181 ORiginal Article High Recurrence Rate of Idiopathic Peptic Ulcers in Long-Term Follow-up Hyuk Yoon, Sang Gyun Kim, Hyun Chae Jung, and In Sung Song
More informationManagement of dyspepsia and of Helicobacter pylori infection
Management of dyspepsia and of Helicobacter pylori infection The University of Nottingham John Atherton Wolfson Digestive Diseases Centre University of Nottingham, UK Community management of dyspepsia
More informationUpdate on the pathological classification of gastritis. Hala El-Zimaity, M.D. M.S. Epidemiology McMaster University Hamilton, Ontario Canada
Update on the pathological classification of gastritis Hala El-Zimaity, M.D. M.S. Epidemiology McMaster University Hamilton, Ontario Canada CLASSIFICATION GASTRITIS GASTROPATHY 1. Acute 2. Chronic 3. Uncommon
More informationImmunoglobulin G Antibody against Helicobacter pylori: Clinical Implications of Levels Found in Serum
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, Sept. 2002, p. 1044 1048 Vol. 9, No. 5 1071-412X/02/$04.00 0 DOI: 10.1128/CDLI.9.5.1044 1048.2002 Copyright 2002, American Society for Microbiology. All Rights
More informationPeptic Ulcer Disease Update
Peptic Ulcer Disease Update Col Pat Storms RAM 2005 Disclosure Information 84th Annual AsMA Scientific Meeting Col Patrick Storms I have no financial relationships to disclose. I will discuss the following
More informationTRANSPARENCY COMMITTEE OPINION. 13 December 2006
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 13 December 2006 HELIKIT 75 mg, powder for oral solution CIP : 343 132-1 Applicant : MAYOLY SPINDLER 13 Curea anhydrous
More informationPrevalence of Multiple White and Flat Elevated Lesions in Individuals Undergoing a Medical Checkup
doi: 10.2169/internalmedicine.9808-17 http://internmed.jp ORIGINAL ARTICLE Prevalence of Multiple White and Flat Elevated Lesions in Individuals Undergoing a Medical Checkup Kyoichi Adachi 1, Tomoko Mishiro
More informationResearch Article First-Line Helicobacter pylori Eradication in Patients with Chronic Kidney Diseases in Taiwan
Hindawi BioMed Research International Volume 2017, Article ID 3762194, 7 pages https://doi.org/10.1155/2017/3762194 Research Article First-Line Helicobacter pylori Eradication in Patients with Chronic
More informationTHE PREVALENCE OF HELICBACTER PYLORI AMONG PATIENTS COMPLAINING FROM ABDOMINAL PAIN
THE PREVALENCE OF HELICBACTER PYLORI AMONG PATIENTS COMPLAINING FROM ABDOMINAL PAIN Ahed J. Al-Khatib Jordan University of Science and Technology, Jordan Ahmed Saber Abu-zaiton Al-albayt University Abstract
More informationHelicobacter pylori: Diagnosis, treatment and risks of untreated infection
Helicobacter pylori: Diagnosis, treatment and risks of untreated infection Klaus Mönkemüller Department of Gastroenterology, Hepatology und Infectius Diseases Otto-von-Guericke University, Magdeburg bb
More informationClinical Policy Title: Noninvasive testing for H. pylori
Clinical Policy Title: Noninvasive testing for H. pylori Clinical Policy Number: 08.01.04 Effective Date: January 1, 2016 Initial Review Date: August 19, 2015 Most Recent Review Date: August 17, 2016 Next
More informationClinical Policy Title: Noninvasive testing for H. pylori
Clinical Policy Title: Noninvasive testing for H. pylori Clinical Policy Number: 08.01.05 Effective Date: January 1, 2016 Initial Review Date: August 19, 2015 Most Recent Review Date: August 17, 2017 Next
More informationEffect of Helicobacter pylori eradication on the regression of gastric polyps in National Cancer Screening Program
ORIGINAL ARTICLE Korean J Intern Med 2018;33:506-511 Effect of Helicobacter pylori eradication on the regression of gastric polyps in National Cancer Screening Program Su Youn Nam 1,2, Bum Joon Park 2,
More informationH.pylori IgA Cat #
DIAGNOSTIC AUTOMATION, INC. 23961 Craftsman Road, Suite D/E/F, Calabasas, CA 91302 Tel: (818) 591-3030 Fax: (818) 591-8383 onestep@rapidtest.com technicalsupport@rapidtest.com www.rapidtest.com See external
More informationAn update on Helicobacter pylori infection in renal failure patients
Immunopathol Persa. 2016;2(2):e10 Review Immunopathologia Persa http www.immunopathol.comm An update on Helicobacter pylori infection in renal failure patients Mohammad Reza Ardalan 1, Saeed Mardani 2,
More informationHelicobacter pylori-specific IgG in chronic haemodialysis patients: relationship of hypergastrinaemia to positive serology
Nephrol Dial Transplant (1996) 11: 120-124 Original Article Nephrology Dialysis Transplantation Helicobacter pylori-specific IgG in chronic haemodialysis patients: relationship of hypergastrinaemia to
More informationAcid-Peptic Diseases of the Stomach and Duodenum Including Helicobacter pylori and NSAIDs Prof. Sheila Crowe
Acid-Peptic Diseases of the Stomach and Duodenum Including Helicobacter pylori and NSAIDs 1 Division of Gastroenterology UC San Diego School of Medicine Clinical presentations of Helicobacter pylori infection
More informationHelicobacter pylori Improved Detection of Helicobacter pylori
DOI:http://dx.doi.org/10.7314/APJCP.2016.17.4.2099 RESEARCH ARTICLE Improved Detection of Helicobacter pylori Infection and Premalignant Gastric Mucosa Using Conventional White Light Source Gastroscopy
More informationCorrelation Between Endoscopic and Histological Findings in Different Gastroduodenal Lesion and its Association with Helicobacter Pylori
ORIGINAL ARTICLE Correlation Between Endoscopic and Histological Findings in Different Gastroduodenal Lesion and its Association with Helicobacter Pylori *A. Sultana 1, SM Badruddoza 2, F Rahman 3 1 Dr.
More informationClinical Policy Title: Noninvasive testing for H. pylori
Clinical Policy Title: Noninvasive testing for H. pylori Clinical Policy Number: 08.01.04 Effective Date: January 1, 2016 Initial Review Date: August 19, 2015 Most Recent Review Date: August 17, 2016 Next
More informationMEDICAL POLICY EFFECTIVE DATE: 05/19/11 REVISED DATE: 05/24/12, 05/23/13 ARCHIVED DATE: 05/22/14 EDITED DATE: 05/28/15, 05/25/16, 05/18/17, 05/17/18
MEDICAL POLICY SUBJECT: NON-INVASIVE HELICOBACTER PAGE: 1 OF: 6 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product, including
More informationIndex. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Adherence, to bismuth quadruple therapy, 543 546 Adjuvant therapy, probiotics as, 567 569 Age factors, in gastric cancer, 611 612, 616 AID protein,
More informationKEYWORDS Dyspepsia, Acid Peptic Disease, Helicobacter Pylori, Urease, Giemsa, Peptic Ulcer, Non-Ulcer Dyspepsia.
INCIDENCE OF HELICOBACTER PYLORI WITH ACID PEPTIC DISEASE AND MALIGNANT CONDITIONS OF UPPER GASTROINTESTINAL TRACT IN A TERTIARY CENTRE - A PROSPECTIVE STUDY Karunamoorthy Rajachidambaram 1, Dinkaran Kaarthesan
More informationRelationship of Helicobacter pylori Infection with Gastric Black Spots Shown by Endoscopy
doi: 10.2169/internalmedicine.1751-18 http://internmed.jp ORIGINAL ARTICLE Relationship of Helicobacter pylori Infection with Gastric Black Spots Shown by Endoscopy Kyoichi Adachi 1, Takumi Notsu 1, Tomoko
More informationSee external label 2 C-8 C Σ=96 tests Cat # 1505Z. MICROWELL ELISA H.Pylori IgA Cat # 1505Z
DIAGNOSTIC AUTOMATION, INC. 23961 Craftsman Road, Suite E/F, Calabasas, CA 91302 Tel: (818) 591-3030 Fax: (818) 591-8383 onestep@rapidtest.com technicalsupport@rapidtest.com www.rapidtest.com See external
More informationACG Clinical Guideline: Treatment of Helicobacter pylori Infection
ACG Clinical Guideline: Treatment of Helicobacter pylori Infection William D. Chey, MD, FACG 1, Grigorios I. Leontiadis, MD, PhD 2, Colin W. Howden, MD, FACG 3 and Steven F. Moss, MD, FACG 4 1 Division
More informationClinical Policy Title: Noninvasive testing for H. pylori
Clinical Policy Title: Noninvasive testing for H. pylori Clinical Policy Number: 08.01.05 Effective Date: January 1, 2016 Initial Review Date: August 19, 2015 Most Recent Review Date: July 3, 2018 Next
More informationH.Pylori IgG
DIAGNOSTIC AUTOMATION, INC. 21250 Califa Street, Suite 102 and116, Woodland Hills, CA 91367 Tel: (818) 591-3030 Fax: (818) 591-8383 onestep@rapidtest.com technicalsupport@rapidtest.com www.rapidtest.com
More informationH.Pylori IgG Cat # 1503Z
DIAGNOSTIC AUTOMATION, INC. 23961 Craftsman Road, Suite D/E/F, Calabasas, CA 91302 Tel: (818) 591-3030 Fax: (818) 591-8383 onestep@rapidtest.com technicalsupport@rapidtest.com www.rapidtest.com See external
More informationPrevalence of gastrointestinal symptoms in Brunei Darussalam
Gastrointestinal symptoms in Brunei 39 Prevalence of gastrointestinal symptoms in Brunei Darussalam Vui Heng Chong, Gastroenterology Unit, Department of Medicine, Raja Isteri Pengiran Anak Saleha (RIPAS)
More informationResearch Article Performance of Routine Helicobacter pylori Invasive Tests in Patients with Dyspepsia
Gastroenterology Research and Practice Volume 2013, Article ID 184806, 5 pages http://dx.doi.org/10.1155/2013/184806 Research Article Performance of Routine Helicobacter pylori Invasive Tests in Patients
More informationRelationship between Helicobacter Pylori infection and iron deficiency anemia in hemodialysis patients
International Journal of Multidisciplinary Research and Development Online ISSN: 2349-4182, Print ISSN: 2349-5979 Impact Factor: RJIF 5.72 www.allsubjectjournal.com Volume 5 Issue 7; July 2018; Page No.
More informationFecoprevalence and determinants of Helicobacter pylor infection among asymptomatic children in Myanmar
International Journal of Gastroenterology, Hepatology, Transplant & Nutrition Original Article Fecoprevalence and determinants of Helicobacter pylor infection among asymptomatic children in Myanmar Hnin
More informationDisclosures. Co-founder and Chief Science Officer, TechLab
H. pylori testing Disclosures Co-founder and Chief Science Officer, TechLab Learning Objectives Evaluate the appropriate testing methodology by balancing performance, economics, and workflow. Discuss the
More informationComparison of the Accuracy of Two Commercial Rapid Urase Tests, CLOtest and Pronto Dry, in Detecting Helicobacter pylori Infection ABSTRACT
Original Article Rojborwonwitaya J, Vijitjunyakul N THAI J GASTROENTEROL 2005 Vol. 6 No. 2 May - Aug. 2005 55 Comparison of the Accuracy of Two Commercial Rapid Urase Tests, CLOtest and Pronto Dry, in
More informationRisk Factors for the Presence of Symptoms in Peptic Ulcer Disease
ORIGINAL ARTICLE Clin Endosc 2017;50:578-584 https://doi.org/10.5946/ce.2016.129 Print ISSN 2234-2400 / On-line ISSN 2234-2443 Open Access Risk Factors for the Presence of Symptoms in Peptic Ulcer Disease
More informationJune By: Reza Gholami
ACG/CAG guideline on Management of Dyspepsia June 2017 By: Reza Gholami DEFINITION OF DYSPEPSIA AND SCOPE OF THE GUIDELINE Dyspepsia was originally defined as any symptoms referable to the upper gastrointestinal
More informationMANAGEMENT OF DYSPEPSIA AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT OF DYSPEPSIA AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) Routine endoscopic investigation of patients of any age, presenting with dyspepsia
More informationHelicobacter 2008;13:1-6. Am J Gastroent 2007;102: Am J of Med 2004;117:31-35.
An Update on Helicobacter pylori and Its Treatment Trenika Mitchell, PharmD, BCPS Clinical Assistant Professor University of Kentucky College of Pharmacy October 18, 2008 Objectives Review the epidemiology
More informationClinical Policy Title: Breath Testing for H. Pylori
Clinical Policy Title: Breath Testing for H. Pylori Clinical Policy Number: 08.01.04 Effective Date: January 1, 2016 Initial Review Date: August 19, 2015 Most Recent Review Date: August 19, 2015 Next Review
More informationDERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT OF DYSPEPSIA
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT OF DYSPEPSIA o Patients of any age with ALARM signs should be referred through the 2-week referral system o Routine endoscopic investigation
More informationCharacteristics of gastric cancer in negative test of serum anti-helicobacter pylori antibody and pepsinogen test: a multicenter study
Gastric Cancer (2017) 20:764 771 DOI 10.1007/s10120-016-0682-5 ORIGINAL ARTICLE Characteristics of gastric cancer in negative test of serum anti-helicobacter pylori antibody and pepsinogen test: a multicenter
More informationHelicobacter Connections. Barry Marshall
Helicobacter Connections Barry Marshall The greatest obstacle to knowledge is not ignorance, it is the illusion of knowledge. Daniel Boorstein - Historian Peptic Ulcers Duodenal Ulcer (DU) Gastric Ulcer
More informationRegression of Advanced Gastric MALT Lymphoma after the Eradication of Helicobacter pylori
Gut and Liver, Vol. 6, No. 2, April 2012, pp. 270-274 CASE REPORT Regression of Advanced Gastric MALT Lymphoma after the Eradication of Helicobacter pylori Soo-Kyung Park, Hwoon-Yong Jung, Do Hoon Kim,
More informationA Study of the Correlation between Endoscopic and Histological Diagnoses in Gastroduodenitis
000-9 70/8 7/80S-0749 THE AMERICAN JOIIRNAE. OF GAsrR()E.NrER 1987 by Am. Coll.ofGastroenterology Vo!.8. No. 8, 1487 Printed in U.S.A. A Study of the Correlation between Endoscopic
More informationProton Pump Inhibitor Induction of Gastric Cobblestone-like Lesions in the Stomach
doi: 10.2169/internalmedicine.7964-16 Intern Med Advance Publication http://internmed.jp ORIGINAL ARTICLE Proton Pump Inhibitor Induction of Gastric Cobblestone-like Lesions in the Stomach Kosuke Takahari
More informationEDUCATION PRACTICE. Persistent Helicobacter pylori Infection After a Course of Antimicrobial Therapy What s Next? Clinical Scenario.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2008;6:1086 1090 EDUCATION PRACTICE Persistent Helicobacter pylori Infection After a Course of Antimicrobial Therapy What s Next? RICHARD J. SAAD* and WILLIAM D.
More informationAstraZeneca and Daiichi Sankyo Launch Proton Pump Inhibitor Nexium 10 mg and 20 mg Granules for Suspension, Sachet, in Japan
AstraZeneca K.K. Daiichi Sankyo Co., Ltd. AstraZeneca and Daiichi Sankyo Launch Proton Pump Inhibitor Nexium 10 mg and 20 mg Granules for Suspension, Sachet, in Japan Osaka and Tokyo, Japan, April 18,
More informationCyclooxygenase-2 Expression in Gastric Antral Mucosa Before and After Eradication of Helicobacter pylori Infection
THE AMERICAN JOURNAL OF GASTROENTEROLOGY Vol. 94, No. 5, 1999 1999 by Am. Coll. of Gastroenterology ISSN 0002-9270/99/$20.00 Published by Elsevier Science Inc. PII S0002-9270(99)00126-4 Cyclooxygenase-2
More informationHelicobacter pylori Eradication within 120 Days Is Associated with Decreased Complicated Recurrent Peptic Ulcers in Peptic Ulcer Bleeding Patients
Gut and Liver, Vol. 9, No. 3, May 2015, pp. 346-352 ORiginal Article Helicobacter pylori Eradication within 120 Days Is Associated with Decreased Complicated Recurrent Peptic Ulcers in Peptic Ulcer Bleeding
More informationOveruse of acid suppressant drugs in patients with chronic renal failure
Nephrol Dial Transplant (2003) 18: 570 575 Original Article Overuse of acid suppressant drugs in patients with chronic renal failure Hans Strid, Magnus Simrén and Einar S. Björnsson Department of Internal
More informationEndoscopic Submucosal Dissection ESD
Endoscopic Submucosal Dissection ESD Peter Draganov MD Professor of Medicine Division of Gastroenterology, Hepatology and Nutrition University of Florida Gastrointestinal Cancer Lesion that Can be Treated
More informationKK College of Nursing Peptic Ulcer Badil D ass Dass, Lecturer 25th July, 2011
KK College of Nursing Peptic Ulcer Badil Dass, Lecturer 25 th July, 2011 Objectives: By the end of this lecture, the students t will be able to: Define peptic pp ulcer Describe the etiology and pathology
More informationH. pylori IgM CLIA kit
H. pylori IgM CLIA kit Cat. No.:DEEL0251 Pkg.Size:96 tests Intended use Helicobacter pylori IgM Chemiluminescence ELISA is intended for use in evaluating the serologic status to H. pylori infection in
More informationEfficacy of the Kyoto Classification of Gastritis in Identifying Patients at High Risk for Gastric Cancer
ORIGINAL ARTICLE Efficacy of the Kyoto Classification of Gastritis in Identifying Patients at High Risk for Gastric Cancer Mitsushige Sugimoto 1,2, Hiromitsu Ban 1, Hitomi Ichikawa 2, Shu Sahara 2, Taketo
More informationGASTROINTESTINAL AND ANTIEMETIC DRUGS. Submitted by: Shaema M. Ali
GASTROINTESTINAL AND ANTIEMETIC DRUGS Submitted by: Shaema M. Ali GASTROINTESTINAL AND ANTIEMETIC DRUGS by: Shaema M. Ali There are four common medical conditions involving the GI system 1) peptic ulcers
More informationHigh use of maintenance therapy after triple therapy regimes in Ireland
High use of maintenance therapy after triple therapy regimes in Ireland K Bennett, H O Connor, M Barry, C O Morain, J Feely Department of Pharmacology & Therapeutics Department of Gastroenterology Trinity
More informationType of intervention Diagnosis. Economic study type Cost-effectiveness analysis.
Noninvasive tests as a substitute for histology in the diagnosis of Helicobacter pylori infection Hahn M, Fennerty M B, Corless C L, Magaret N, Lieberman D A, Faigel D O Record Status This is a critical
More informationA Heaney, J S A Collins, RGPWatson, R J McFarland, K B Bamford, T C K Tham
186 Royal Victoria Hospital, Belfast, A Heaney J S A Collins Department of Medicine, Queen s University, Belfast, RGPWatson Ulster Hospital, Dundonald, R J McFarland T C K Tham Department of Microbiology
More informationDr. LEUNG Lok Hang, Will
Direct access endoscopy booking by family physicians: evaluating a new service model and clinical predictors of positive endoscopy findings at primary care setting Dr. LEUNG Lok Hang, Will Department of
More informationGastric atrophy: use of OLGA staging system in practice
Gastroenterology and Hepatology From Bed to Bench. 2016 RIGLD, Research Institute for Gastroenterology and Liver Diseases ORIGINAL ARTICLE Gastric atrophy: use of OLGA staging system in practice Mahsa
More informationPART ONE. Peritoneal Kinetics and Anatomy
PART ONE Peritoneal Kinetics and Anatomy Advances in Peritoneal Dialysis, Vol. 22, 2006 Paul A. Fein, Irfan Fazil, Muhammad A. Rafiq, Teresa Schloth, Betty Matza, Jyotiprakas Chattopadhyay, Morrell M.
More informationGastroenterology Tutorial
Gastroenterology Tutorial Gastritis Poorly defined term that refers to inflammation of the stomach. Infection with H. pylori is the most common cause of gastritis. Most patients remain asymptomatic Some
More informationGastrointestinal pathology 2018 lecture 4. Dr Heyam Awad FRCPath
Gastrointestinal pathology 2018 lecture 4 Dr Heyam Awad FRCPath Topics to be covered Peptic ulcer disease Hiatal hernia Gastric neoplasms Peptic ulcer disease (PUD)= chronic gastric ulcer Causes H pylori
More informationPeptic ulcer disease. Nomin-Erdene. D SOM-531
Peptic ulcer disease Nomin-Erdene. D SOM-531 Learning objectives Stomach gross anatomy PUD Epidemiology Pathogenesis Clinical manifestation Diagnosing Treatment Complicated ulcer disease Surgical procedures
More informationH. pylori IgM. Cat # H. pylori IgM ELISA. ELISA: Enzyme Linked Immunosorbent Assay. ELISA - Indirect; Antigen Coated Plate
DIAGNOSTIC AUTOMATION, INC. 23961 Craftsman Road, Suite D/E/F, Calabasas, CA 91302 Tel: (818) 591-3030 Fax: (818) 591-8383 onestep@rapidtest.com technicalsupport@rapidtest.com www.rapidtest.com H. pylori
More informationÐÑÏÓÊÅÊËÇÌÅÍÅÓ ÎÅÍÏÃËÙÓÓÅÓ ÁÍÁÊÏÉÍÙÓÅÉÓ ÅËËÇÍÙÍ ÅÑÅÕÍÇÔÙÍ
ÐÑÏÓÊÅÊËÇÌÅÍÅÓ ÎÅÍÏÃËÙÓÓÅÓ ÁÍÁÊÏÉÍÙÓÅÉÓ ÅËËÇÍÙÍ ÅÑÅÕÍÇÔÙÍ 205 206 ÐÑÏÓÊÅÊËÇÌÅÍÅÓ ÎÅÍÏÃËÙÓÓÅÓ ÁÍÁÊÏÉÍÙÓÅÉÓ ÅËËÇÍÙÍ ÅÑÅÕÍÇÔÙÍ EPITHELIAL CELL TURNOVER IN NON-DYSPLASTIC GASTRIC MUCOSA ADJACENT TO EARLY AND
More informationGilles Jequier. Commercial Director Organobalance, a Novozymes Company
"Latest clinical Evidences showing that a proprietary Lactobacillus reuteri Strain can reduce the Symptoms associated with a Helicobacter pylori Infection" Gilles Jequier Commercial Director Organobalance,
More information- Helicobacter - THE EASE AND DIFFICULTY OF A NEW DISCOVERY. Robin Warren
- Helicobacter - THE EASE AND DIFFICULTY OF A NEW DISCOVERY Robin Warren EARLY DAYS First reports 100 years ago considered spirochaetes 1940 Freedburg saw curved organisms in the stomach 1954 Palmer: Freedburg
More informationA bleeding ulcer: What can the GP do? Gastrointestinal bleeding is a relatively common. How is UGI bleeding manifested? Who is at risk?
Focus on CME at the University of British Columbia A bleeding ulcer: What can the GP do? By Robert Enns, MD, FRCP Gastrointestinal bleeding is a relatively common disorder affecting thousands of Canadians
More information